TumorGen is developing a novel drug discovery platform to identify unseen therapeutic targets associated with cancer metastasis. Our patented technology is used to capture circulating metastatic cancer cell clusters (MCCCs). The MCCCs have been shown to be the primary vector for disseminating distant metastases in most solid tumor cancers. Our innovative platform can open an entirely new therapeutic target space for biopharma developing drugs directly impacting the pathways of cancer metastasis.
Company Details
- Employees
- 5
- Founded
- -
- Address
- 6185 Cornerstone Court East,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- tumorgenmdx.com
- HQ
- San Diego, CA
Tumorgen, Inc. Questions
Tumorgen, Inc.'s website is tumorgenmdx.com
Tumorgen, Inc.'s LinkedIn profile is https://www.linkedin.com/company/tumorgen-mdx-llc
Tumorgen, Inc. has
5 employees.
View email and phone details for 5
employees at Tumorgen, Inc..
Tumorgen, Inc.'s industry is
Biotechnology Research
Tumorgen, Inc.'s top competitors are
Nanocellect Biomedical, Inc.,
Palm Therapeutics,
Myogene Bio,
Styx Biotechnologies,
Origami Therapeutics, Inc.,
Navega Therapeutics,
Nanotools Bioscience,
Resolute Science,
F5 Therapeutics Incorporated,
Papillon Therapeutics.
Tumorgen, Inc.'s categories are Biotechnology Research
Tumorgen, Inc.'s founding year is 2017
